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Impact of renal transplantation on survival in end-stage renal In the general population, obesity is defined as a body
disease patients with elevated body mass index. mass index (BMI) 30 kg/m2, and is associated with
Background. Cadaveric renal transplantation is associated higher rates of hypertension, diabetes, cardiovascularwith a survival advantage compared with dialysis patients re-
disease, and premature death [1, 2]. Among renal trans-maining on the renal transplantation waiting list, but this advan-
plant recipients, obesity either at the time of or aftertage has not been confirmed in obese end-stage renal disease
(ESRD) patients. renal transplantation has been associated with shortened
Methods. Using data from the USRDS, we studied 7521 allograft and patient survival [3, 4], although the results
patients who presented with ESRD from 1 April 1995 to 29 are conflicting [5]. Obesity is among the reasons end-June 1999 and later enrolled on the renal transplantation wait-
stage renal disease (ESRD) patients are not placed oning list with body mass indices (BMI) 30 kg/m2 at the time
the renal transplant waiting list, albeit with considerableof presentation to ESRD, and followed until 6 November 2000.
Recipients of preemptive renal transplantation or organs other variation by center [6]. However, obesity also has been
than kidneys were excluded. Cox non-proportional hazards shown to be associated with improved survival among
regression models were used to calculate adjusted, time-depen- patients on maintenance dialysis, compared to patientsdent hazard ratios (HR) for time to death in a given patient
who are non-obese [7–9].during the study period, controlling for renal transplantation,
Because of the above observations, the survival benefitdemographics and comorbidities (Form 2728).
Results. The incidence of mortality was 3.3 episodes per 100 of renal transplantation seen for all patients with ESRD
patient-years (PY) in cadaveric renal transplantation and 1.9/ on the transplant waiting list [10] might not apply to
100 PY in living donor renal transplantation compared with
patients who are obese. We hypothesized that despite6.6 episodes/100 PY in all patients on the transplant waiting
these findings, the all-cause adjusted survival for obeselist. In comparison to maintenance dialysis, both recipients of
patients is still superior after renal transplantation com-solitary cadaveric kidneys (HR 0.39, 95% CI 0.33 to 0.47), and
recipients of living donor kidneys (HR 0.23, 95% CI 0.16 to pared with remaining on dialysis on the renal transplant
0.34) had statistically significant improved survival. A benefit waiting list, as many of the metabolic and intravascular
of cadaveric renal transplantation did not apply to patients
volume abnormalities associated with dialysis-dependentwith BMI 41 kg/m2 (HR 0.47, 95% CI, 0.17 to 1.25, P 
ESRD would improve with a functioning allograft. There-0.13).
Conclusions. Obese patients on the renal transplant waiting fore, we analyzed data from the United States Renal
list had a significantly lower risk of mortality after renal trans- Data System (USRDS). Our null hypothesis was that
plantation compared with those remaining on dialysis. there was no relationship between renal transplantation
and mortality for obese patients with ESRD placed on
the renal transplant waiting list.1 The opinions are solely those of the authors and do not represent an
endorsement by the Department of Defense or the National Institutes
of Health. This is a U.S. Government work. There are no restrictions
on its use. METHODS
We analyzed a national registry (the USRDS) [11]Key words: obesity, body mass index, renal transplant, living donor,
cadaveric organs, survival, wait list, dialysis, ESRD, USRDS. in a historical cohort study of the association of renal
transplantation with patient survival among obese pa-
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tients enrolled on the renal transplant waiting list. Infor-and in revised form July 29, 2002
Accepted for publication August 12, 2002 mation on comorbidity, as well as height and weight
to calculate BMI, was obtained from the USRDS file 2003 by the International Society of Nephrology
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SAF.MEDEVID. This file is derived from the Center formed with Chi-square testing for categorical variables
and the Student t test for continuous variables. Variablesfor Medicare and Medicaid Studies (formerly HCFA)
medical evidence form (2728) starting with a sample of with P 0.10 in univariate analysis for a relationship with
elevated BMI were entered into multivariable analysisESRD patients prior to April 1995 and universal after-
ward, and has been validated for use in research [12]. as covariates. Continuous variables were examined for
outliers, and values3 SD from the mean were removedFirst, patients were selected who initiated ESRD therapy
between April 1, 1995 and June 29, 1999 who had data from analysis with the exception of height and weight.
Outliers were removed from BMI after calculation, assufficient to calculate BMI. From this cohort, patients
enrolled on the renal transplant waiting list were se- defined earlier, as per prior reports [4].
Stepwise Cox regression non-proportional hazardslected, excluding any dates of listing prior to April 1,
1995. The date when patients on the renal transplant analysis modeled the association between renal trans-
plantation as a segmented time-dependent variable withwaiting list first received a renal transplant also was ex-
tracted, and any dates prior to April 1, 1995 excluded. all-cause mortality, controlling for BMI, race, age, gen-
der, year of first dialysis session, cause of ESRD (diabe-Recipients of organs other than kidneys and of trans-
plants without preceding dialysis were excluded. We then tes or glomerulonephritis), and additional variables from
the medical evidence form, including diabetes and hyper-created two cohorts, the “obese cohort,” defined as pa-
tients with BMI 30 kg/m2 at the time of presentation tension as comorbidities distinct from causes of ESRD,
and ESRD network, as the independent variables. Be-to ESRD, and for purposes of validation, the “non-obese
cohort,” defined as patients whose BMI was 30 kg/m2 cause BMI was not normally distributed in the study
population, it was analyzed as a categorical variable byat that same time. The variables included in the USRDS
standard analysis files (SAFs), as well as data collection quartiles. Because the effect of body size previously has
been shown to be independent of dialysis adequacy [8],methods and validation studies, are listed at the USRDS
website (www.usrds.org), under ‘Researcher’s Guide to and because indices of dialysis adequacy were not avail-
able for the entire population of dialysis patients, dialysisthe USRDS Database’, Section E, ‘Contents of all the
SAFs’ (Standard Analysis Files), and published in the adequacy was not assessed in this study. Survival analysis
compared all transplant recipients versus patients on theUSRDS. The demographics of the end-stage renal dis-
ease population have been previously described (2001 transplant waiting list. Survival analysis assessing living
donor transplants censored cadaveric transplant recipi-USRDS report). Dialysis patients younger than age 65
are eligible for Medicare 90 days after starting dialysis. ents at the time of transplant, and analysis of cadaveric
recipients censored living donor recipients at the timeTherefore, hospitalization and mortality data may be
incomplete during the first 90 days after dialysis initiation of transplant.
Survival time was calculated as the time from the datefor patients younger than 65, but starts immediately after
transplant. of the first listing for transplant until death, or latest
available follow-up date. In contrast to the previous ver-The file SAF.PATIENTS was used as the primary data
set, including cause of renal disease (PDIS) and cause sions of USRDS that were coordinated by the University
of Michigan, after the 1999 USRDS report and SAFs,and date of patient death. SAF.RXHIST was used to
obtain follow-up dates. The file SAF.TXWAIT contains the USRDS was coordinated by the University of Min-
nesota. In these files, follow-up dates (the variablethe date patients in the above cohort were first placed
on the transplant waiting list. The file SAF.MEDEVID ENDDATE) were intentionally left blank in the file
RXHIST after patients received transplants. In directincludes data from the Medical Evidence Form (2728).
The file SAF.TXUNOS included information on trans- consultation with the USRDS, we were instructed to
substitute the most recent follow-up date in the databaseplant donor type, pre-transplant dialysis, previous trans-
plant, and multiple organ transplants. Files were merged (6 November 2000) for missing follow-up dates for trans-
plant patients (personal communication, Dr. A.J Collinsusing unique patient identifiers. Details on anthropomet-
ric measurements or nutritional parameters other than and Dr. S. Chen, January 2002, and later reiterated in
the 2001 Researcher’s Guide to the USRDS, www.usrds.serum albumin were unavailable. No information on pa-
tient medications was available (for the entire cohort of org). In order to account for potential biases, survival
times were calculated using two methods. In the firstpatients) except for the use of pre-dialysis erythropoie-
tin. The USRDS researcher’s agreement specifically pro- method, we did not remove patients from the category
of listing for transplant if they were removed from thishibits patient contact or chart review.
All analyses were performed using SPSS 9.0 (SPSS, category at a later time, nor did we remove patients from
the category of renal transplant recipient if they laterInc., Chicago, IL, USA). Files were merged and con-
verted to SPSS files using DBMS/Copy (Conceptual experienced graft loss, in intent to treat fashion. This
methodology was in accordance with all previous studies,Software, Houston, TX, USA). Statistical significance
was defined as P  0.05. Univariate analysis was per- and was most comparable with previous results. How-
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Fig. 1. Diagram of study population extraction. Abbreviations are: ESRD, end-stage renal disease; BMI, body mass index in kg/m2; CAD, cadaveric;
LD, living donor.
ever, potential bias applies to that approach. Mortality under-represented and diabetics were over represented.
Characteristics of the obese cohort are shown in Table 1.is higher after graft loss, compared with a functioning
allograft. Therefore, survival time also was calculated As shown, there were significant differences between
patients who were transplanted and those who were not,censoring patients at the date of graft loss. We also per-
even after patients were placed on the transplant waitingformed stratified analysis limited to patients with body
list. Patients who were transplanted were more likely tomass indices 40 kg/m2 in order to determine if there
have started dialysis earlier (due to the waiting timewas a critical threshold of BMI above which no benefit
for renal transplant), older, have higher serum albuminof renal transplantation could be demonstrated. Hierar-
levels, and less likely to be African American, have pe-chically well-formed models were used for assessment
ripheral vascular disease, or have BMI 35.8 kg/m2. Forof interaction terms in all models.
the obese cohort, the mean time from listing to trans-
plantation was 0.89  0.77 (range 0.1 to 3.5) years for
RESULTS cadaveric transplant recipients. Mean follow-up times
Of 348,615 patients who initiated ESRD therapy in (in years) for both the obese and non-obese cohort are
the USRDS database from April 1, 1995 to June 29, given in Table 2.
1999, 43,707 were subsequently entered on the renal Figure 2 shows the distribution of BMI for the entire
transplant waiting list, and of these, 40,493 were entered cohort of wait-listed patients (N 40,493) over the years
on the waiting list on or after April 1, 1995. Of these, of the study. The increase in BMI by year was statistically
88% had sufficient information from the medical evi- significant in linear regression analysis (beta for year
dence form (2728) to calculate BMI. Figure 1 shows the of first ESRD service  0.18, P  0.001). BMI after
strategy for patient extraction for the study population. presentation to ESRD was only available for patients
The mean date of first ESRD service was January 14, who received transplants, and this information was from
1997. The mean transplant date was December 25, 1997, the time of transplant. BMI could not be calculated for
and the most recent transplant date was November 16, 57.9% of transplant recipients at the time of transplant
1999. The study had 51 months of accrual and 29 months due to missing data. However, for those who had com-
of additional follow-up. Compared to patients who did plete data, 35.2% had an increase in BMI from the time
not have known BMI, patients with known BMI were of presentation to ESRD to the time of transplant, and
64.8% had a decrease in BMI. Of the transplant recipi-of similar age and gender, but African Americans were
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Table 1. Characteristics of patients with ESRD with BMI 30 kg/m2 placed on the renal transplant waiting list, who presented to ESRD
from April 1, 1995 to June 29, 1999 with valid follow-up dates (total N  7443)
AOR for transplantationb P value
Transplanted during study vs. not 30.5% (2293) NA NA
Male vs. female 54.4% (4091)
African American vs. all other races 35.2% (2651) 0.47 (0.42–0.54) 0.0001
Cause of ESRD
Diabetes vs. all other causes 40.0% (3012)
Glomerulonephritis 24.3% (1784)
Hypertension 18.3% (1344)
Age years, per older year 48.112.0 0.98 (0.97–0.99) 0.0001
Year of first dialysis per later year 0.57 (0.54–0.61) 0.0001
Variables from the Medical Evidence Forma
Weight kg 96.213.6
Height cm 167.911.6
Body mass index kg/m2 34.13.6
Body mass index 35.8 (4th Quartile vs. 1st) 0.80 (0.67–0.94) 0.007
Serum Albumin gm/dL, per increase in quartile 3.40.6 1.13 (1.08–1.19) 0.0001
Hematocrit % 28.25.3a
Congestive heart failure 14.7% (1108)
Hemodialysis vs. peritoneal dialysis 80.1% (5866)
Medicare coverage 18.7% (1405)
Peripheral vascular disease vs. absent 5.3% (402) 0.74 (0.56–0.97) 0.03
Data given as the % of total (counts) or mean  standard deviation. ESRD is end-stage renal disease. Exclusion criteria (as per Methods section) were patients
transplanted without preceding dialysis, or organs other than kidneys and they were excluded from analysis.
a History of condition within the past ten years or value at initiation of treatment for end stage renal disease
b Adjusted odds ratio in logistic regression for association with receipt of renal transplant during the study period (Odds ratios above one reflect positive association
with renal transplantation)
Table 2. Patient death rates in obese (30 kg/m2 BMI) patients placed on the renal transplant waiting list, who presented to ESRD from
April 1, 1995 to June 29, 1999, followed through November 2000
Mean follow-up Death rate per 100
Category N Deaths time years patient-years at risk
Obese cohort
All patients on the renal transplant waiting list 7,443 1278 2.611.22 6.6
Cadaveric recipients 1,719 200 3.481.10 3.3
Living donor recipients 552 35 3.351.07 1.9
Nonobese cohort
All patients on the renal transplant waiting list 23,219 3968 2.701.27 6.3
Cadaveric recipients 4,795 505 3.821.02 2.8
Living donor recipients 1,528 77 3.821.0 1.3
Exclusion criteria as per methods: patients transplanted without preceding dialysis, or organs other than kidneys were excluded from analysis.
ents with BMI 30 kg/m2 at the time of ESRD, only significantly reduced risk of mortality for both recipients
of solitary cadaver kidneys (61%) and of living donor12.5% for whom data were available had BMI30 kg/m2
at the time of transplant, and were included in the obese kidneys (77%) in the obese cohort. In the non-obese
cohort, the adjusted hazard ratio for cadaveric renalcohort. Because of the large percentage of patients with
missing data, we did not perform a statistical analysis transplantation was identical to that for the obese cohort,
but with narrower confidence intervals (0.39, 95% CI,using BMI at the time of transplant.
Table 2 shows death rates for the study population, 0.35 to 0.43, P  0.0001).
Of the obese cohort, 213 (9.4%) of patients trans-by all patients on the waiting list and by renal transplant
recipients. After cadaveric renal transplantation, patient planted experienced graft loss after transplantation dur-
ing the study period. Analysis using the same methodssurvival rates at one and three years were 95% and
90.9%, respectively. Table 3 shows the results of Cox and covariates also was performed censoring patients at
the date of graft loss, to account for potential bias. Inregression analysis of factors associated with patient
mortality, analyzing solitary cadaveric renal transplanta- this analysis, the adjusted hazard ratio for cadaveric renal
transplantation in the obese cohort was 0.35 (95% CI,tion as a segmented time-dependent variable, adjusted
for age, race, cause of ESRD, year of first dialysis, pres- 0.29 to 0.42; P  0.0001. Similar analysis was not per-
formed for living donor transplant recipients, since theence of congestive heart failure, and serum albumin level.
As shown, renal transplantation was associated with a rates of graft loss were much lower than for cadaveric
Glanton et al: Renal transplantation in ESRD patients with elevated BMI 651
Fig. 2. Box plots of the body mass index
(BMI, in kg/m2) of patients on the renal trans-
plant waiting list who presented with ESRD
on or after 4/1/1995 to 6/29/1999 (N 31,014),
stratified by year of first ESRD service. The
majority of outliers had BMI 40 kg/m2.
There was a significant increase in mean BMI
over the time of the study period (in linear
regression, beta for year of first ESRD 0.18,
P  0.001). The numbers to the right of outli-
ers are USRDS ID numbers used for merging
files, and cannot be used to identify patients.
Table 3. Cox regression analysis of associations with mortality in ESRD patients with obesity (BMI 30 kg/m2) on the renal transplant
waiting list, who presented to ESRD from April 1, 1995 to June 29, 1999
Solitary cadaveric recipientsa Solitary living donor recipientsa
Characteristics P value AHR (95% CI)c P value AHR (95% CI)c
Renal transplantationb 0.0001 0.39 (0.33–0.47) 0.0001 0.23 (0.16–0.34)
Age per increase in year 0.0001 1.03 (1.02–1.04) 0.0001 1.03 (1.02–1.04)
Year of first ESRD treatment per more recent year 0.0001 0.82 (0.77–0.88) 0.0001 0.77 (0.72–0.83)
Diabetes as cause of ESRD vs. all other causes 0.0001 1.81 (1.55–2.11) 0.0001 1.86 (1.60–2.18)
Variables from Medical Evidence Form 2728
PVD vs. absent 0.005 1.74 (1.42–2.12) 0.004 1.70 (1.39–1.64)
CHF vs. absent 0.0001 1.42 (1.22–1.65) 0.0001 1.40 (1.19–1.66)
Quartiles of serum albumin per higher quartile 0.0001 0.87 (0.81–0.93) 0.0001 0.87 (0.82–0.93)
BMI per higher quartile 0.03 1.06 (1.00–1.14) 0.14 1.04 (0.99–1.10)
African American vs. all other races 0.0001 0.66 (0.59–0.78) 0.0001 0.62 (0.53–0.73)
Multivariable analysis (by Cox non-proportional hazards regression) of factors associated with obesity in patients placed on the renal transplant waiting list, 1
April 1995 to 29 June 1999. Only variables significant in the final model (P  0.05 by Cox regression analysis) are shown. Abbreviations are: AHR, adjusted hazard
ratio for mortality; CHF, congestive heart failure; 95% CI, 95% confidence intervals; ESRD, end-stage renal disease; CHF, cardiac failure; PVD, peripheral vascular
disease listed as a comorbidity on form 2728.
a Analysis for CR: censored living donor recipients at the time of transplant; analysis for LR, censored cadaveric recipients at the time of transplant
b The time-dependent covariate, for renal transplantation: 1 after the time of renal transplantation, 0 else
c Adjusted hazard ratio for all-cause mortality. Hazard ratios greater than one reflect a positive association with mortality
recipients. For the non-obese cohort, the corresponding tis, and malignancy at 2.7% each. In the first two months
after transplant, six obese transplant recipients died. Thehazard ratio was 0.33 (95% CI 0.30 to 0.37, P  0.0001).
In the analysis limited to patients with BMI41 kg/m2 leading cause of death in obese transplant recipients was
sepsis due to peritonitis (33%), with 17% of causes of(N  458), renal transplantation was no longer signifi-
cantly associated with mortality (adjusted hazard ratio, death listed as blank or unknown, with other causes of
death evenly distributed between atherosclerotic heart0.47, 95% CI 0.17 to 1.25, P  0.13). For patients with
a BMI 30 kg/m2 up to 40 kg/m2, renal transplantation disease, cardiomyopathy, and malignancy. Among wait-
listed patients who did not receive transplants duringwas significantly associated with lower mortality com-
pared with remaining on the renal transplant waiting list. the study, causes of death were missing or unknown in
33.3% of patients. The leading specified causes of deathAmong all renal transplant recipients, 46.8% of causes
of death were blank or unknown. The leading specified were cardiac arrest, cause unknown (19.1%), acute myo-
cardial infarction (9.3%), sepsis, other (6.8%), cardiaccauses of death were cardiac arrest, cause unknown
(9%), septicemia, non-specified (9%), acute myocardial arrhythmia (4.6%), stroke (3.3%), sepsis due to periph-
eral vascular disease/gangrene (2.2%), and sepsis due toinfarction (4.3%), and pulmonary embolism (3.2%), fol-
lowed by cardiomyopathy, stroke, sepsis due to peritoni- peritonitis (2.1%).
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DISCUSSION appear to be in the best interest of obese ESRD patients
to undergo renal transplantation.The present study shows that obese patients with
The reasons for an apparent survival benefit of renalESRD have improved survival after renal transplanta-
transplantation have already been discussed [9]. Thetion compared with remaining on the renal transplant
demonstration of a benefit of renal transplantation inwaiting list. A statistically significant benefit was seen
obese patients with ESRD underscores the importancefor obese recipients of both cadaveric and living donor
of comparing high-risk groups not just with other renalkidneys, similar to the benefit of renal transplantation
transplant recipients, but also with similar patients onpreviously shown for the entire population of patients
the renal transplant waiting list. Such an approach hadon the renal transplant waiting list [9]. It is remarkable
been used previously for ESRD patients with hepatitisthat the benefit of renal transplantation applied to all
C [13], recipients of marginal donor kidneys [14], andbut the most morbidly obese patients on the waiting list
diabetic recipients of combined kidney-pancreas trans-(those with BMI 41 kg/m2).
plants [15].It is clearly important for providers and patients alike
The limitations of this study are common to all retro-to know the relative prognosis for obese transplant recip-
spective analyses of databases. Selection bias could haveients compared with non-obese transplant recipients.
arisen because of misclassification errors or missing data.However, it is perhaps more relevant to individual pa-
Even after placement on the renal transplant waitingtients to know the prognosis of such patients after renal
list, selection bias still occurred in the renal transplanttransplantation compared with remaining on dialysis.
process, similar to previous studies [8, 16]. The methodsWeight loss is recommended for potential transplant can-
of adjustment and stratification used in the present studydidates who are obese, and in fact the majority of trans-
are similar to those used in previous studies, with theplant recipients for whom data were available did achieve
added advantage of comorbidity and laboratory dataa decrease in BMI at the time of transplant, although
from the Medical Evidence Form, which has not pre-only 12.5% achieved a BMI of 30 kg/m2. However,
viously been used in such analyses. However, higher
many times weight loss does not achieve the desired
BMI was independently associated with mortality in the
goals. Given the significant increase in BMI among pa- present analysis, indicating that there were still subcate-
tients on the renal transplant waiting list over time docu- gories of BMI that affected mortality differently in this
mented in this study, the importance of elevated BMI population (that is, morbidly obese vs. obese), in contrast
in renal transplantation will likely increase. to the relationship seen in all chronic dialysis patients
Because obesity is perceived as a negative factor in [6–8]. Information bias could have arisen from case selec-
both listing and receipt of renal transplantation, it could tion, especially given the necessary exclusion of most
be argued that obese candidates for renal transplantation transplant recipients during the years studied. Our study
had to be healthier than non-obese candidates to receive confirmed that survival for both patients on the trans-
renal transplantation. However, the findings of the pres- plant waiting list and transplant recipients improved over
ent study are strengthened by the inclusion of baseline time in comparison with the previous study of Wolfe et
comorbidity data, which the study of Wolfe et al could al [10], and consistent with other studies [17, 18]. In
not assess due to recent changes in the Medical Evidence addition, demographic characteristics and mortality rates
Form (2728) [10]. This suggests that the apparent survival in our study were comparable to previously published
benefit of renal transplantation in obese ESRD patients reports, given differences in the population and years
was not due to selection bias. The magnitude of the studied. Our study was limited by the lack of complete
apparent survival benefit of renal transplantation for data in many of the fields, particularly for height and
obese ESRD patients and non-obese ESRD patients ap- weight to calculate BMI. However, the study still ob-
pears to be similar, according to the present study. Many tained BMI for more than 75% of all US ESRD patients
transplant professionals have been reluctant to offer during that period, from whom the study population was
transplantation to obese candidates for fear of surgical extracted. The study design allowed adequate follow-
complications after transplant. The high rate of infec- up after renal transplantation to avoid survival bias in
tious death after transplant in obese recipients in the comparison to wait-listed patients.
present study is consistent with the findings of Meier- It is possible that exclusion of transplant recipients
Kriesche, Arndorfer and Kaplan, who found that obesity who did not have dialysis prior to transplantation or who
was most strongly associated with infectious death after underwent transplantation without enrollment on the
transplant [4]. Despite this, due to the high rate of cardio- renal transplant waiting list further underestimated the
vascular death among patients on the renal transplant number of transplant recipients, similar to the techniques
waiting list, renal transplantation offered a net survival of Wolfe et al [10] and Ojo et al [15]. Such patients had
advantage for these patients. Therefore, although results no survival times prior to transplantation for comparison.
Wolfe et al (in both of the previous studies) emphasizedfor individual patients can never be predicted, it would
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plant obesity on renal transplant outcomes. Clin Transplant 11:493–that survival comparisons of renal transplant recipients
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with dialysis patients should be limited to dialysis pa- 4. Meier-Kriesche HU, Arndorfer JA, Kaplan B: The impact of
body mass index on renal transplant outcomes: A significant inde-tients on the renal transplant waiting list, since dialysis
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hemodialysis, and mortality. Am J Kidney Dis 35:80–88, 2000these patients still had BMI 30 kg/m2 despite losing
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after renal transplantation, such as blood pressure [20] in all patients on dialysis, patients on dialysis awaiting transplanta-
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